Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q2L4Q9
UPID:
PRS53_HUMAN
Alternative names:
Polyserine protease 3
Alternative UPACC:
Q2L4Q9
Background:
Serine protease 53, also known as Polyserine protease 3, is a unique enzyme with the capability to degrade the fibrinogen alpha chain as well as pro-urokinase-type plasminogen activator in vitro. This protein, identified by the accession number Q2L4Q9, plays a pivotal role in the modulation of fibrinolysis and plasminogen activation, processes essential for maintaining hemostatic balance.
Therapeutic significance:
Understanding the role of Serine protease 53 could open doors to potential therapeutic strategies. Its involvement in the degradation of key components in the fibrinolytic system suggests a possible target for modulating blood clot dissolution, which is crucial in the treatment of thrombotic disorders.